Agenus (AGEN) Competitors

$3.58 +0.11 (+3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$3.55 -0.03 (-0.73%)

As of 04:25 PM Eastern

AGEN vs. CBIO, XOMA, EBS, RIGL, and VSTM

Should you buy Agenus stock or one of its competitors? MarketBeat compares Agenus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agenus include Crescent Biopharma (CBIO), XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.

How does Agenus compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by company insiders. Comparatively, 5.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Crescent Biopharma has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Agenus has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, Agenus had 10 more articles in the media than Crescent Biopharma. MarketBeat recorded 15 mentions for Agenus and 5 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.46 beat Agenus' score of -0.30 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Agenus	50.49%	-31.66%	42.71%

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	49.23	-$153.94M	-$10.91	N/A
Agenus	$114.20M	1.31	$120K	$1.59	2.25

Crescent Biopharma presently has a consensus target price of $28.00, indicating a potential upside of 31.89%. Agenus has a consensus target price of $14.50, indicating a potential upside of 305.03%. Given Agenus' higher possible upside, analysts clearly believe Agenus is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Agenus beats Crescent Biopharma on 11 of the 17 factors compared between the two stocks.

How does Agenus compare to XOMA Royalty?

XOMA Royalty (NASDAQ:XOMA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by insiders. Comparatively, 5.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

XOMA Royalty has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Agenus has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

In the previous week, Agenus had 11 more articles in the media than XOMA Royalty. MarketBeat recorded 15 mentions for Agenus and 4 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of -0.02 beat Agenus' score of -0.30 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a net margin of 50.49% compared to XOMA Royalty's net margin of 45.75%. XOMA Royalty's return on equity of 10.32% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	45.75%	10.32%	3.49%
Agenus	50.49%	-31.66%	42.71%

XOMA Royalty has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	9.60	$31.71M	$1.46	28.77
Agenus	$114.20M	1.31	$120K	$1.59	2.25

XOMA Royalty presently has a consensus target price of $53.75, indicating a potential upside of 27.98%. Agenus has a consensus target price of $14.50, indicating a potential upside of 305.03%. Given Agenus' higher probable upside, analysts clearly believe Agenus is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

XOMA Royalty beats Agenus on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Emergent Biosolutions?

Agenus (NASDAQ:AGEN) and Emergent Biosolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Agenus had 14 more articles in the media than Emergent Biosolutions. MarketBeat recorded 15 mentions for Agenus and 1 mentions for Emergent Biosolutions. Emergent Biosolutions' average media sentiment score of 1.00 beat Agenus' score of -0.30 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market.

Agenus has a net margin of 50.49% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Emergent Biosolutions has higher revenue and earnings than Agenus. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.31	$120K	$1.59	2.25
Emergent Biosolutions	$742.90M	0.57	$52.60M	-$0.28	N/A

61.5% of Agenus shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 5.5% of Agenus shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Agenus currently has a consensus target price of $14.50, suggesting a potential upside of 305.03%. Emergent Biosolutions has a consensus target price of $12.00, suggesting a potential upside of 46.61%. Given Agenus' higher probable upside, research analysts clearly believe Agenus is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Agenus and Emergent Biosolutions tied by winning 7 of the 14 factors compared between the two stocks.

How does Agenus compare to Rigel Pharmaceuticals?

Agenus (NASDAQ:AGEN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Agenus currently has a consensus target price of $14.50, suggesting a potential upside of 305.03%. Rigel Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 70.74%. Given Agenus' higher probable upside, research analysts clearly believe Agenus is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Agenus has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Agenus. MarketBeat recorded 18 mentions for Rigel Pharmaceuticals and 15 mentions for Agenus. Rigel Pharmaceuticals' average media sentiment score of -0.24 beat Agenus' score of -0.30 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.31	$120K	$1.59	2.25
Rigel Pharmaceuticals	$299.77M	1.97	$367.02M	$18.72	1.71

Rigel Pharmaceuticals has a net margin of 121.50% compared to Agenus' net margin of 50.49%. Rigel Pharmaceuticals' return on equity of 47.99% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

61.5% of Agenus shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 5.5% of Agenus shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats Agenus on 12 of the 16 factors compared between the two stocks.

How does Agenus compare to Verastem?

Verastem (NASDAQ:VSTM) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Verastem currently has a consensus target price of $15.60, suggesting a potential upside of 231.21%. Agenus has a consensus target price of $14.50, suggesting a potential upside of 305.03%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Verastem has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Agenus has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

In the previous week, Agenus had 4 more articles in the media than Verastem. MarketBeat recorded 15 mentions for Agenus and 11 mentions for Verastem. Verastem's average media sentiment score of 0.08 beat Agenus' score of -0.30 indicating that Verastem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	13.39	-$209.47M	-$2.70	N/A
Agenus	$114.20M	1.31	$120K	$1.59	2.25

Agenus has a net margin of 50.49% compared to Verastem's net margin of -391.17%. Agenus' return on equity of -31.66% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-391.17%	-486.40%	-91.56%
Agenus	50.49%	-31.66%	42.71%

88.4% of Verastem shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 5.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Agenus beats Verastem on 11 of the 17 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$149.07M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	2.25	18.81	20.87	25.61
Price / Sales	1.31	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-0.65	6.75	9.86	6.71
Net Income	$120K	$24.11M	$3.55B	$333.77M
7 Day Performance	-4.53%	0.11%	-0.26%	0.40%
1 Month Performance	-24.15%	0.87%	1.39%	4.03%
1 Year Performance	3.17%	78.18%	41.07%	36.33%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	1.9475 of 5 stars	$3.58 +3.2%	$14.50 +305.0%	+2.7%	$149.07M	$114.20M	2.25	440	Trending News Earnings Report Analyst Downgrade Analyst Revision
CBIO Crescent Biopharma	2.1408 of 5 stars	$18.52 -1.3%	$28.00 +51.2%	N/A	$516.97M	$10.84M	N/A	50
XOMA XOMA Royalty	3.5061 of 5 stars	$41.50 -0.9%	$53.75 +29.5%	+52.1%	$499.15M	$52.15M	28.42	10
EBS Emergent Biosolutions	2.0709 of 5 stars	$8.98 -5.5%	$12.00 +33.6%	+42.3%	$490.62M	$742.90M	N/A	2,420	Analyst Downgrade
RIGL Rigel Pharmaceuticals	2.8337 of 5 stars	$26.20 +0.6%	$51.50 +96.6%	+75.7%	$481.79M	$294.28M	1.40	160	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. CBIO, XOMA, EBS, RIGL, and VSTM

How does Agenus compare to Crescent Biopharma?

Summary

How does Agenus compare to XOMA Royalty?

Summary

How does Agenus compare to Emergent Biosolutions?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Summary

How does Agenus compare to Verastem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. CBIO, XOMA, EBS, RIGL, and VSTM

How does Agenus compare to Crescent Biopharma?

Do institutionals and insiders have more ownership in CBIO or AGEN?

Which has more volatility & risk, CBIO or AGEN?

Does the media favor CBIO or AGEN?

Is CBIO or AGEN more profitable?

Which has stronger valuation & earnings, CBIO or AGEN?

Do analysts prefer CBIO or AGEN?

Summary

How does Agenus compare to XOMA Royalty?

Do insiders & institutionals have more ownership in XOMA or AGEN?

Which has more risk & volatility, XOMA or AGEN?

Does the media favor XOMA or AGEN?

Is XOMA or AGEN more profitable?

Which has higher valuation and earnings, XOMA or AGEN?

Do analysts rate XOMA or AGEN?

Summary

How does Agenus compare to Emergent Biosolutions?

Does the media refer more to AGEN or EBS?

Which has more risk & volatility, AGEN or EBS?

Is AGEN or EBS more profitable?

Which has better earnings & valuation, AGEN or EBS?

Do institutionals & insiders hold more shares of AGEN or EBS?

Do analysts prefer AGEN or EBS?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Do analysts prefer AGEN or RIGL?

Which has more risk & volatility, AGEN or RIGL?

Does the media refer more to AGEN or RIGL?

Which has better earnings & valuation, AGEN or RIGL?

Is AGEN or RIGL more profitable?

Do institutionals & insiders hold more shares of AGEN or RIGL?

Summary

How does Agenus compare to Verastem?

Do analysts prefer VSTM or AGEN?

Which has more volatility and risk, VSTM or AGEN?

Does the media prefer VSTM or AGEN?

Which has preferable earnings and valuation, VSTM or AGEN?

Is VSTM or AGEN more profitable?

Do insiders and institutionals hold more shares of VSTM or AGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools